Skip to main content
OpenTrials
Completed

NCT Number: NCT02167464

Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study

Comparative Effectiveness Research using an intent-to-treat approach in 8 clinics in South Carolina. The investigators will assess 4 efficacious approaches to controlling treatment-resistant hypertension (TRH): Aldosterone Antagonist, Referral to Hypertension Specialist, Renin Treatment-Guided Therapeutics, and combination of Hypertension Specialist and Renin Treatment-Guided Therapeutics. Patients with TRH are evaluated with the BpTRU device for an accurate and representative blood pressure measure on two occasions before entry into the study. Qualitative data from focus group discussions with practice staff, and patient surveys and interviews will provide contextual data to help explain why some interventions are more acceptable and successful than others.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

AnMed, Anderson, South Carolina, United States

Loading trial locations.

About this study

This is Comparative Effectiveness Research conducted in the real world of under-resourced primary care clinics in South Carolina. Four arms of the study are identified with two clinics/arm enrolling and following patients with TRH. The goal is to compare rates of BP control according to American Heart Association guidelines among the 4 arms, along with clinic and patient satisfaction with each approach.

Our hypothesis is that defining pathophysiological mechanisms (e.g. renin treatment-guided therapeutics) with or without referral to a hypertension specialist will improve blood pressure control over adding an aldosterone antagonist in eligible patients or just referring patients to a hypertension specialist.

This mixed-methods design captures medical and qualitative data to not only describe the outcome of blood pressure control, but to assess the impact of the four interventions on staff and patient satisfaction. Key patient data includes demographics, visits, blood pressure values, medications and laboratory data. Focus group discussions with practice staff before and after the study will document early attitudes toward each arm, any practice changes needed to implement each arm and any burdens of the intervention on the practice. Patient surveys and interviews will assess their satisfaction with each intervention along with their experiences in participating in this research project.

Treatment Resistant Hypertension is a common medical condition, and relatively ineffective treatment regimens are a significant contributing factor. The long-term goal is to establish practice and effective approaches for controlling blood pressure and reducing clinical complications and related health disparities.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of Treatment Resistant Hypertension (TRH)
  • On three or more hypertensive medications at therapeutic dose
  • BpTRU measurement on two occasions of >135/85 without diabetes or chronic kidney disease or BP >125/75 if diabetes and/or chronic kidney disease.
  • Mean of >10 BP readings of >135/85 mm mercury for those with no diabetes or chronic kidney disease
  • Mean of >10 home BP readings of >125/75 mm mercury for those with diabetes and/or chronic kidney disease.

Exclusion criteria

  • Less than 18 years of age
  • Refuses or incompetent to provide consent
  • BP controlled to goal in or outside the clinic
  • Symptomatic or significant orthostatic hypotension (<20/10 on standing)
  • Life-threatening or severe illness
  • Currently on protocol
  • Myocardial Infarction or stroke in the past 6 months
  • Estimated Glomerular Filtration Rate <50 ml/1.7/min.

Treatment and study plan

Renin treatment-guided Therapeutics

Drug

Patients are treated based upon their renin levels according to an approved algorithm.

Referral Hypertension specialist

Other

Patients are referred to a hypertension specialist.

Aldosterone Antagonist

Drug

Spironolactone 12.5 - 25mg daily

Primary outcomes

  1. blood pressure control

    Time frame: four months

    Blood pressure control will be assessed according to guidelines established by American Heart Association.

Sponsors and collaborators

Lead sponsor

Medical University of South Carolina

Other

Collaborators

  • University of South Carolina

Registry information

Acronym: TRH

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Jun 19, 2014
Registry last updated
Jul 23, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.